Minerva Neurosciences (NERV) Short-Term Debt repayments (2014 - 2015)
Minerva Neurosciences posted quarterly Short-Term Debt repayments of $195656.0 for Q1 2015, down 85.85% on a QoQ basis from $1.4 million in Q3 2014.
Minerva Neurosciences (NERV) has 2 years of Short-Term Debt repayments data on file, last reported at $195656.0 in Q1 2015.
- For the quarter ending Q1 2015, Short-Term Debt repayments changed N/A year-over-year to $195656.0; the trailing twelve-month figure through Dec 2015 stood at $195656.0 (changed N/A YoY), and the FY2015 full-year result was $195656.0, down 89.61% from the prior year.
- Short-Term Debt repayments for Q1 2015 stood at $195656.0, down from $1.4 million in the prior quarter.
- Across five years, Short-Term Debt repayments topped out at $1.4 million in Q3 2014 and bottomed at $195656.0 in Q1 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 102,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2015 | 195,656.00 |
| Mar 31, 2015 | 195,656.00 |
| Sep 30, 2014 | 1.38 Mn |
| Sep 30, 2014 | 1.38 Mn |